The dopaminergic basis of cognitive and motor performance in Alzheimer's disease

Neurobiology of Disease

Volumn 37, Issue 2, 2010, Pages 477-482

  Reeves, Suzanne ^a   Mehta, Mitul ^a,b   Howard, Robert ^a   Grasby, Paul ^b   Brown, Richard ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

11C Raclopride; Alzheimer's disease; Cognitive; D2 receptor; Dopamine; Motor; Neurochemistry; PET; Striatal

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; RACLOPRIDE C 11;

ADULT; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BINDING AFFINITY; CLINICAL ARTICLE; COGNITION; DATA ANALYSIS; DOPAMINERGIC SYSTEM; HUMAN; IN VIVO STUDY; MOTOR PERFORMANCE; NIGRONEOSTRIATAL SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WORD RECOGNITION;

ALZHEIMER DISEASE; ATTENTION; BINDING, COMPETITIVE; BRAIN CHEMISTRY; BRAIN MAPPING; COGNITION; COGNITION DISORDERS; CORPUS STRIATUM; DISABILITY EVALUATION; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; MOVEMENT; MOVEMENT DISORDERS; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2;

EID: 73049116696     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.11.005     Document Type: Article

References (60)

1. Arnsten A.F. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn. Sci. 2 (1998) 436-446
2. Backman L., Ginovart N., Dixon R.A., Wahlin T.B., Wahlin A., Halldin C., and Farde L. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am. J. Psychiatry 157 (2000) 635-637
3. 1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J. Pharmacol. Exp. Ther. 283 (1997) 183-189
4. 2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. Neuroimage 40 (2008) 1287-1295
5. 3 receptor density: a single photon emission computed tomography study. Psychol. Med. 35 (2005) 197-204
6. Cohen M.X., Krohn-Grimberghe A., Elger C.E., and Weber B. Dopamine gene predicts the brain's response to dopaminergic drug. Eur. J. Neurosci. 26 (2007) 3652-3660
7. Crofts H.S., Dalley J.W., Collins P., Van Denderen J.C., Everitt B.J., Robbins T.W., and Roberts A.C. Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cereb. Cortex 11 (2001) 1015-1026
8. Cropley V.L., Fujita M., Innis R.B., and Nathan P.J. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol. Psychiatry 59 (2006) 898-907
9. Erixon-Lindroth N., Farde L., Wahlin T.B., Sovago J., Halldin C., and Backman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 138 (2005) 1-12
10. Fern-Pollak L., Whone A.L., Brooks D.J., and Mehta M.A. Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease. Neuropsychologia 42 (2004) 1917-1926
11. Flaherty A.W., and Graybiel A.M. Input-output organization of the sensorimotor striatum in the squirrel monkey. J. Neurosci. 14 (1994) 599-610
12. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
13. Frank M.J., and O'Reilly R.C. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav. Neurosci. 120 (2006) 497-517
14. Friston K., Holmes A.P., Worsley K.J., Poline J.-P., Frith C.D., and Frackowiak R.S.J. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 2 (1995) 189-210
15. Gerardin E., Pochon J.B., Poline J.B., Tremblay L., Van de Moortele P.F., Levy R., Dubois B., Le Bihan D., and Lehericy S. Distinct striatal regions support movement selection, preparation and execution. Neuroreport 15 (2004) 2327-2331
16. Gotham A.M., Brown R.G., and Marsden C.D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 111 Pt 2 (1988) 299-321
17. Haber S.N., Fudge J.L., and McFarland N.R. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J. Neurosci. 20 (2000) 2369-2382
18. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., and Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27 (2007) 1533-1539
19. 18F-fluorodopa and PET. Ann. Nucl. Med. 8 (1994) 245-251
20. Jankowski J., Scheef L., Huppe C., and Boecker H. Distinct striatal regions for planning and executing novel and automated movement sequences. Neuroimage 44 (2009) 1369-1379
21. Joel D., and Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96 (2000) 451-474
22. Jones G.M., Sahakian B.J., Levy R., Warburton D.M., and Gray J.A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl.) 108 (1992) 485-494
23. 2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology 19 (1998) 472-480
24. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., and Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 49 (2006) 603-615
25. 2 receptors correlate with memory functions in Alzheimer's disease. Eur. J. Neurosci. 18 (2003) 149-154
26. Lawrence A.D., Weeks R.A., Brooks D.J., Andrews T.C., Watkins L.H., Harding A.E., Robbins T.W., and Sahakian B.J. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 121 Pt. 7 (1998) 1343-1355
27. 11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J. Cereb. Blood Flow Metab. 14 (1994) 995-1010
28. Marchand W.R., Lee J.N., Thatcher J.W., Hsu E.W., Rashkin E., Suchy Y., Chelune G., Starr J., and Barbera S.S. Putamen coactivation during motor task execution. Neuroreport 19 (2008) 957-960
29. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.R., Huang Y., Simpson N., Ngo K., Van Heertum R., and Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab. 21 (2001) 1034-1057
30. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
31. Mehta M.A., and Riedel W.J. Dopaminergic enhancement of cognitive function. Curr. Pharm. Des. 12 (2006) 2487-2500
32. Middleton F.A., and Strick P.L. Basal ganglia output and cognition: evidence from anatomical, behavioral, and clinical studies. Brain Cogn. 42 (2000) 183-200
33. Montgomery A.J., Thielemans K., Mehta M.A., Turkheimer F., Mustafovic S., and Grasby P.M. Correction of head movement on PET studies: comparison of methods. J. Nucl. Med. 47 (2006) 1936-1944
34. 2 receptor binding with age in rhesus monkeys: importance of correction for differences in striatal size. J. Cereb. Blood Flow Metab. 19 (1999) 218-229
35. Murray A.M., Weihmueller F.B., Marshall J.F., Hurtig H.I., Gottleib G.L., and Joyce J.N. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann. Neurol. 37 (1995) 300-312
36. Passetti F., Levita L., and Robbins T.W. Sulpiride alleviates the attentional impairments of rats with medial prefrontal cortex lesions. Behav. Brain Res. 138 (2003) 59-69
37. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., and Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 (2003) 1127-1135
38. Pezze M.A., Dalley J.W., and Robbins T.W. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride. Psychopharmacology (Berl) 202 (2009) 307-313
39. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., and Perry E.K. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 122 Pt. 8 (1999) 1449-1468
40. 3) receptor availability and delusions in Alzheimer disease. Neurology 72 (2009) 528-534
41. 2) receptor availability in spatial cognition. Neuroimage 28 (2005) 216-226
42. 11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 50 (1998) 152-156
43. Robbins T.W., James M., Owen A.M., Sahakian B.J., McInnes L., and Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5 (1994) 266-281
44. Roberts A.C., De Salvia M.A., Wilkinson L.S., Collins P., Muir J.L., Everitt B.J., and Robbins T.W. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J. Neurosci. 14 (1994) 2531-2544
45. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141 (1984) 1356-1364
46. Rowe J.B., Hughes L., Ghosh B.C., Eckstein D., Williams-Gray C.H., Fallon S., Barker R.A., and Owen A.M. Parkinson's disease and dopaminergic therapy-differential effects on movement, reward and cognition. Brain 131 (2008) 2094-2105
47. 1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251 (1991) 947-950
48. Seamans J.K., Gorelova N., Durstewitz D., and Yang C.R. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J. Neurosci. 21 (2001) 3628-3638
49. Selemon L.D., and Goldman-Rakic P.S. Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J. Neurosci. 5 (1985) 776-794
50. Spraker M.B., Yu H., Corcos D.M., and Vaillancourt D.E. Role of individual basal ganglia nuclei in force amplitude generation. J. Neurophysiol. 98 (2007) 821-834
51. 2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann. Nucl. Med. 17 (2003) 567-573
52. van Gaalen M.M., Brueggeman R.J., Bronius P.F., Schoffelmeer A.N., and Vanderschuren L.J. Behavioral disinhibition requires dopamine receptor activation. Psychopharmacology (Berl) (2006)
53. Vingerhoets F.J., Schulzer M., Calne D.B., and Snow B.J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann. Neurol. 41 (1997) 58-64
54. Volkow N.D., Gur R.C., Wang G.J., Fowler J.S., Moberg P.J., Ding Y.S., Hitzemann R., Smith G., and Logan J. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 155 (1998) 344-349
55. Ward R.D., Kellendonk C., Simpson E.H., Lipatova O., Drew M.R., Fairhurst S., Kandel E.R., and Balsam P.D. Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits. Behav. Neurosci. 123 (2009) 720-730
56. 11C]raclopride: optimization and signal-to-noise considerations. J. Nucl. Med. 41 (2000) 522-530
57. 1 receptors in prefrontal cortex. Nature 376 (1995) 572-575
58. Williams J., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., and Rawlins J.N.P. Haloperidol reduces Stroop interference and increases negative priming in healthy people. Schizophr. Res. 18 (1996) 223
59. Yang Y.K., Yeh T.L., Chiu N.T., Lee I.H., Chen P.S., Lee L.C., and Jeffries K.J. Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia. Psychiatry Res. 131 (2004) 209-216
60. 1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J. Neurosci. 17 (1997) 8528-8535